Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company that has incurred an accumulated deficit of $312.8 million as of September 30, 2026. The company is focused on developing its lead product candidates, onzotrigine and LTG-321, and anticipates continued substantial losses as it funds research and development.
Cogent Communications reported Q3 2026 service revenue of $231.2 million, a 1.8% sequential decrease, while Adjusted EBITDA rose 3.9% to $73.9 million. The company highlighted strong growth in wavelength revenue, which increased 57% year-over-year, and announced non-binding letters of intent to sell four data centers for approximately $100 million.
Term
Q3 2026
“On November 5, 2026, Cogent Communications Holdings, Inc. issued a press release summarizing its financial results for the third quarter of 2026.”
David Schaeffer, President and Chief Executive Officer
REGENXBIO Inc. reported total assets of $466.0 million as of September 30, 2026, with a significant increase in cash and cash equivalents to $95.8 million compared to $34.5 million at year-end 2025. The company is currently managing clinical holds on its RGX-121 and RGX-111 programs while continuing development partnerships with AbbVie and Nippon Shinyaku.
Vistance Networks reported a significant increase in net income to $6,833.7 million for the nine months ended September 30, 2026, primarily driven by a $6,736.3 million gain from discontinued operations. During the period, the company completed major divestitures resulting in $12.4 billion in net proceeds, which were used to repay $7.37 billion in long-term debt and fund $3.44 billion in special distributions to common stockholders.
Verisk Analytics reported Q3 2026 revenues of $544.0 million, with net income attributable to Verisk of $128.2 million. The company maintained a strong liquidity position with a $2.0 billion syndicated revolving credit facility and reported diluted earnings per share of $3.0 for the quarter.
Zenas BioPharma, Inc. reported a significant increase in liquidity as of September 30, 2026, with cash, cash equivalents, and short-term investments totaling approximately $585.3 million, up from $343.2 million at the end of 2025. The company continues to operate as a non-accelerated filer and emerging growth company, focusing on the development of product candidates for immunology and inflammation diseases.
Certara reported third-quarter 2026 revenues of $94.9 million, a 4.4% increase year-over-year, and net income of $5.6 million. However, for the nine months ended September 30, 2026, the company recorded a net loss of $58.4 million, primarily driven by a significant $37.0 million loss from discontinued operations.
Lincoln International reported record third-quarter 2026 revenue of $293.7 million, a 57% increase year-over-year, driven by strong growth in Investment Banking Advisory and the acquisition of MarshBerry. The company achieved GAAP net income of $9.9 million ($0.25 per diluted share) and adjusted net income of $50.2 million ($0.46 per adjusted diluted share).
Term
Q3 2026
“Lincoln delivered a record third quarter, achieving new highs in both revenue and adjusted earnings, with strong growth across our Investment Banking Advisory and Valuations and Opinions businesses. We are entering the fourth quarter from a position of strength, supported by healthy pipeline activity and continued client engagement. Looking ahead, we remain focused on executing our long-term strategy through continued investment in our people, technology and global platform to further strengthen our competitive position and drive sustainable growth.”
Rob Brown, Chief Executive Officer of Lincoln International
TIC Solutions reported record third quarter 2026 revenue of $639.6 million, a 35% increase year-over-year primarily driven by the acquisition of NV5. Despite a net loss of $11.1 million, the company achieved record combined backlog of $1.29 billion and increased its full-year 2026 revenue outlook.
Term
Q3 2026
“We delivered a record third quarter. On a combined basis, revenue grew 12.5%, including organic growth of 8.4%, Adjusted EBITDA grew 19%, and Adjusted EBITDA margin expanded approximately 90 basis points to 16.8%.”
Ben Heraud, CEO of TiC Solutions
“This quarter’s results reinforce the strategic rationale of bringing Acuren and NV5 together. Our recent acquisitions add complementary capabilities and client relationships that broaden our growth opportunities in strategic end markets, service lines, and geographies.”
Robert A.E. Franklin, Executive Chairman of TiC Solutions
Verisk Analytics reported third quarter 2026 financial results with revenue of $809 million, up 5.3% year-over-year, and diluted adjusted EPS of $1.96. The company highlighted strong subscription growth of 8.2% and reaffirmed its full-year 2026 guidance targets.
Term
Q3 2026
“Our strong third-quarter results underscore the resilience of our subscription-based business model and the mission-critical role Verisk plays in the insurance ecosystem. We are executing with discipline against our strategic priorities by deepening client partnerships, accelerating AI-powered innovation at scale, and expanding the network effects that connect participants and enhance value across the insurance value chain.”
Lee Shavel, President and CEO
“I'm pleased to share that Verisk delivered third-quarter financial results that returned to levels in line with our annual Investor Day targets and reflect the continued sequential acceleration in growth we previously articulated. In third-quarter 2026, OCC revenue increased 7.4% with strong subscription growth of 8.2% and transactional growth of 3.2%.”
Shutterstock reported Q3 2026 revenue of $173.9 million, a 33% year-over-year decrease driven by weakness in new customer acquisition and data licensing timing. The company recorded a net loss of $197.8 million, which included a $195.6 million non-cash goodwill impairment charge. Additionally, the company announced the appointment of Scott Grossman as Interim CFO, succeeding Rik Powell.
Term
Q3 2026
“During the third quarter, we maintained a strong focus on operational discipline and cost management while navigating continued headwinds in our core Content segment and deal timing volatility in Data Licensing.”
Jon Oringer, Chairman and Chief Executive Officer
“We reduced third-quarter Product Development and SG&A expenses by 30% year-over-year to $96 million, representing $39 million in quarterly savings, while reducing total headcount by 16% year-to-date.”
Centrus Energy Corp. reported its third-quarter 2026 results, highlighting its transition toward domestic HALEU and LEU production under multiple IDIQ contracts with the DOE. The company is navigating geopolitical risks including the Russian Uranium Import Ban and the Russian Decree rescinding TENEX's export license, while planning significant capacity expansions in Piketon, Ohio.
For the six months ended September 30, 2026, McGraw Hill reported revenue of $1.18 billion and net income of $144.2 million, an increase from $105.8 million in the prior year period. The company highlighted risks related to technological developments in artificial intelligence and potential shifts in U.S. Department of Education funding and policy.
Aclaris Therapeutics reported its Q3 2026 financial results, highlighting a cash position of $156.4M which is expected to fund operations through the first half of 2029. The company also provided clinical updates, including positive Phase 1b data for ATI-052 in atopic dermatitis and asthma, and the planned initiation of a Phase 2b trial for modzatinib in the fourth quarter of 2026.
Term
Q3 2026
“Aclaris is developing unique product candidates designed to provide improved therapeutic options across a variety of inflammatory disorders with the goal of raising the efficacy ceiling, and our recent progress reflects continued execution toward that objective.”
Dr. Neal Walker, Chief Executive Officer and Chair of the Board of Directors of Aclaris
C4 Therapeutics reported financial results for the third quarter of 2026, highlighting clinical progress for its lead candidate cemsidomide. The company remains on track to complete enrollment for the Phase 2 MOMENTUM trial in Q1 2027 and expects initial data from multiple combination cohorts in mid-to-late 2027.
“Throughout the year, we have continued to build evidence supporting cemsidomide’s potential as a backbone therapy across the multiple myeloma treatment landscape while advancing our clinical development plan to evaluate cemsidomide in late and earlier lines of therapy.”
Andrew Hirsch, president and chief executive officer of C4 Therapeutics
“With data expected from these trials in 2027, we believe next year will be pivotal in establishing cemsidomide’s therapeutic profile and its potential to address the significant unmet need of patients with multiple myeloma across an evolving standard of care.”
Andrew Hirsch, president and chief executive officer of C4 Therapeutics
Unity Software Inc. reported its third-quarter 2026 results, highlighting steady revenue growth across its Create and Grow Solutions segments. The company emphasized improved operational efficiencies and a narrowing net loss, while reaffirming its full-year financial guidance.
McGraw Hill reported fiscal second quarter 2027 results with revenue of $632.2 million, exceeding expectations despite a 5.5% year-over-year decline. The company highlighted growth in digital revenue and an agentic AI strategy connecting proprietary content to platforms like Microsoft Copilot and Anthropic’s Claude.
Term
Fiscal Q2 2027
“McGraw Hill's first half fiscal year 2027 performance underscores our continued higher education market share gains, scale and deep position of trust serving over 100 million active curriculum licenses across the global education ecosystem.”
Philip Moyer, President, Chief Executive Officer
“Our second quarter results demonstrated digital revenue growth, a strong margin profile and commitment to gross debt reduction. Our first-half performance, including robust re-occurring revenue growth, combined with strengthening indicators of our ability to deliver accelerating growth in fiscal year 2028, reinforces our confidence in our long-term strategy.”
Bob Sallmann, Executive Vice President, Chief Financial Officer
TIC Solutions, Inc. reported a net loss of $11.1 million for the third quarter of 2026, despite a significant revenue increase to $639.6 million compared to $473.9 million in the prior year period. The company's financial position was impacted by higher operating expenses and interest costs, while total assets remained stable at approximately $4.4 billion.
Kimbell Royalty Partners reported record Q3 2026 daily production of 27,565 Boe/d and consolidated Adjusted EBITDA of $80.4 million. The company also announced a quarterly cash distribution of $0.45 per unit and increased its revolving credit facility borrowing base to $750 million.
Term
Q3 2026
“We are pleased to report record third quarter results, which were driven by strong organic growth and the partial contribution from our recent $221.2 million Drop Down acquisition.”
Robert Ravnaas, Chairman and Chief Executive Officer
WW International reported a net income of $15.1 million for the quarter ended September 30, 2026, a significant recovery from a $57.5 million loss in the prior year period. However, for the nine months ended September 30, 2026, the company recorded a net loss of $22.8 million as subscription revenues declined from $170.9 million to $152.0 million year-over-year.
Akebia Therapeutics reported Q3 2026 financial results, highlighted by a 140% year-over-year increase in patients on Vafseo to approximately 11,500. The company reported Vafseo net product revenues of $14.8 million and maintained a strong cash position of $159.3 million as it prepares for expanded market access in 2027.
Term
Q3 2026
“Our strategic commercial priority remains making Vafseo standard of care for the treatment of anemia for patients on dialysis, and we are focused on continuing to increase the number of patients on therapy.”
John P. Butler, Chief Executive Officer of Akebia
“We believe this compelling data has the potential to drive Vafseo to be standard of care. We continue to work to strengthen our market position as we enter 2027 when we believe Vafseo access will expand beyond the Transitional Drug Add-on Payment Adjustment (TDAPA)-only patients to nearly all clinically eligible patients.”
Appian Corp reported third quarter 2026 financial results with total revenue increasing 25% year-over-year to $234.6 million, driven by a 20% rise in cloud subscriptions revenue. The company achieved GAAP net income of $12.3 million ($0.17 per diluted share) and provided full-year 2026 revenue guidance of $873 million to $877 million.
Climb Bio, Inc. is a clinical-stage biotechnology company focused on immunology and autoimmune diseases, specifically developing product candidates budoprutug and CLYM116. As of October 30, 2026, the company had 58,738,178 shares of common stock outstanding and continues to incur significant losses with no current source of product revenue.
Monte Rosa Therapeutics reported a net loss of $84.8 million for the nine months ended September 30, 2026, compared to a net income of $7.5 million in the prior year period, primarily due to lower collaboration revenue. The company significantly strengthened its balance sheet through an underwritten public offering that raised $323.8 million, ending the period with $577.7 million in cash, cash equivalents, and marketable securities.
ConocoPhillips reported Q3 2026 earnings of $4.0 billion ($3.34 per share) and adjusted earnings of $3.9 billion ($3.27 per share), driven by higher realized prices. The company increased its quarterly ordinary dividend by 11% to $0.93 per share and returned $3.4 billion to shareholders during the quarter, including $2.4 billion in share repurchases.
Term
Q3 2026
“ConocoPhillips is continuing to execute our differential strategy, with strong operational and financial performance across the portfolio. We’re capturing efficiencies across our best-in-class Lower 48 assets, growing our strategic commercial LNG offtake portfolio and advancing Willow critical path items.”
Andy O’Brien, president and chief executive officer
“Our differentiated value proposition, underpinned by the deepest, highest-quality upstream portfolio in the sector, positions us to deliver continued CFO and free cash flow growth at an advantaged reinvestment rate well into the next decade.”
Andy O’Brien, president and chief executive officer
Xeris Biopharma reported third quarter 2026 total revenue of $107.2 million, a 44% increase year-over-year, driven primarily by a 93% surge in Recorlev net revenue. The company achieved net income of $11.3 million and raised its full-year 2026 revenue guidance to a range of $395 million to $405 million.
“As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve that is accelerating our Company’s near-term outlook, and we are now on a path to reach more than $1 billion in total revenue in 2030.”
John Shannon, Chairman and Chief Executive Officer
“We now see Recorlev on a path to nearly $1 billion in annual net revenue three to four years sooner than previously expected.”
John Shannon, Chairman and Chief Executive Officer
Envoy Medical reported third quarter 2026 financial results and provided a clinical update on its Acclaim fully implanted cochlear implant. The company reached a six-month follow-up milestone for its full pivotal trial cohort and submitted the second module of its Modular PMA application to the FDA.
“We continued to make significant progress with our investigational fully implanted cochlear implant during the third quarter, as we approach an extremely exciting 2027. Not only did we report encouraging 12-month data from the first 10 participants in our trial, but we also surpassed the three-month follow-up mark for the full cohort. Since quarter end, we have now surpassed the six-month follow-up milestone. We remain on track for all participants to complete their 12-month visits by early in the second quarter of 2027. Each milestone brings us closer to offering cochlear implant candidates a fully implanted option they have wanted for decades.”
Brent Lucas, Chief Executive Officer of Envoy Medical
Certara reported third quarter 2026 financial results with revenue of $94.9 million, driven by 11% growth in software revenue. The company narrowed its full-year 2026 revenue growth guidance to 2-3% and appointed Grant Peterson as Chief Product Officer.
Term
3 months
“I am pleased with the steady progress we are making against our strategic, customer and operational objectives. We delivered solid revenue and profit in the quarter, and software revenue grew 11% organically, our first double-digit quarter in two years. We are focused on the disciplined execution required to deliver this performance consistently.”
Jon Resnick, Chief Executive Officer
“The third quarter reflects continued software momentum and the initial benefits of the operating actions we implemented in the first half. Adjusted EBITDA margin improved to 31.8%, up more than 370 basis points from the second quarter. We generated $30.7 million of cash from continuing operations in the quarter and ended with $214.9 million in cash. With nine months of results reported, we are narrowing our 2026 full year revenue growth range to 2% to 3%.”
Climb Bio reported Q3 2026 financial results, highlighting a cash position of $227.6 million which provides a runway into the second half of 2028. The company initiated dosing in its Phase 2 trial for CLYM116 in IgA nephropathy and reported positive Phase 1 data supporting a best-in-class every-12-week dosing profile.
Term
Q3 2026
“We are building significant momentum across our programs, CLYM116 and budoprutug. For CLYM116, two independent datasets support a best-in-class anti-APRIL profile and initial budoprutug data from our ongoing Phase 2 PrisMN study in primary membranous nephropathy demonstrated meaningful B-cell depletion and immunologic remission at 200 mg, with potential for increased activity at higher doses.”
Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer
“Looking ahead, we are poised to enter 2027 with two promising programs, multiple anticipated data readouts across both, and the potential to initiate pivotal studies.”
Aoife Brennan, M.B., Ch.B., President and Chief Executive Officer
Zenas BioPharma reported third quarter 2026 financial results and provided a corporate update, highlighting the FDA's acceptance of its BLA for obexelimab with a PDUFA date of May 27, 2027. The company ended the quarter with $647.1 million in cash and investments, which it expects will fund operations into 2027 as it prepares for potential commercialization.
Term
Q3 2026
“This quarter we continued to execute across our portfolio as we prepare for the potential commercialization of obexelimab for the treatment of IgG4-RD. Following the FDA’s acceptance of our BLA in the second quarter of this year, and the recent submission of our MAA to the EMA, we remain focused on commercial readiness ahead of the potential launch.”
Lonnie Moulder, Founder and Chief Executive Officer
“Across our broader pipeline, we remain on track to report topline Phase 2 SunStone data in SLE and initial Phase 1 data for our oral IL-17 inhibitor, ZB021, this quarter. We look forward to closing out a very productive year as we turn our attention to 2027 and continue to build toward our vision of becoming a fully integrated, global development and commercial-stage biopharmaceutical company.”
Lonnie Moulder, Founder and Chief Executive Officer